Nicholas Lydon Explained

Nicholas Lydon
Birth Date:1957 2, df=yes
Thesis Title:Studies on the hormone-sensitive adenylate cyclase from bovine corpus luteum
Thesis Year:1982
Thesis Url:http://www.theses.com

Nicholas B. Lydon FRS (born 27 February 1957) is a British scientist and entrepreneur.[1] In 2009, he was awarded the Lasker Clinical Award and in 2012 the Japan Prize for the development of Gleevec, also known as Imatinib, a selective BCR-ABL inhibitor for the treatment of chronic myeloid leukaemia (CML), which converted a fatal cancer into a manageable chronic condition.[2] [3] [4] [5] [6]

Education

Lydon was educated at Strathallan School near Perth, Scotland.[7] He earned a Bachelor of Science degree in biochemistry from the University of Leeds, England in 1978 and received his PhD in biochemistry from the University of Dundee, Scotland in 1982.[8]

Career

In 1982, Lydon accepted a position with Schering-Plough based in France as Chargé de Récherche. Three years later, he moved to Switzerland to work with Ciba-Geigy Pharmaceuticals, with whom he developed Gleevec. In 1997, he established Kinetex Pharmaceuticals in Boston which was acquired by Amgen in 2000, with whom he worked until 2002. Thereafter, he established several companies that continue to develop drugs to treat various conditions.

Honours and awards

Lydon's nomination for the Royal Society reads:

Notes and References

  1. Web site: Nicholas Lydon . www.scienceheroes.com . 2010 . 13 February 2013.
  2. Web site: Lasker – DeBakey Clinical Medical Research Award: Award Description. Lasker Foundation. 16 August 2010.
  3. Web site: Laureates of the Japan Prize . . 2012 . 13 February 2013.
  4. Druker . B. J. . Talpaz . M. . Resta . D. J. . Peng . B. . Buchdunger . E. . Ford . J. M. . Lydon . N. B. . Kantarjian . H. . Capdeville . R. . Ohno-Jones . 10.1056/NEJM200104053441401 . S. . Sawyers . C. L. . Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia . New England Journal of Medicine . 344 . 14 . 1031–1037 . 2001 . 11287972. free .
  5. 10.1038/nm0596-561 . Druker . B. J. . Tamura . S. . Buchdunger . E. . Ohno . S. . Segal . G. M. . Fanning . S. . Zimmermann . J. . Lydon . N. B. . Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells . Nature Medicine . 2 . 5 . 561–566 . 1996 . 8616716. 36102747 .
  6. Buchdunger . E. . Cioffi . C. L. . Law . N. . Stover . D. . Ohno-Jones . S. . Druker . B. J. . Lydon . N. B. . Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors . The Journal of Pharmacology and Experimental Therapeutics . 295 . 1 . 139–145 . 2000 . 10991971.
  7. Web site: Dr Nicholas Lydon . University of Dundee . 2011 . 13 February 2013 . https://web.archive.org/web/20130517065457/http://www.ppu.mrc.ac.uk/resources/Nick_Lydon_Laureation.doc . 17 May 2013 . dead .
  8. PhD . Nicholas B.. Lydon . Studies on the hormone-sensitive adenylate cyclase from bovine corpus luteum . . 1982 . Nicholas Lydon.
  9. Web site: Dr Nicholas Lydon . . 2013 . 29 May 2013.
  10. Web site: GlaxoSmithKline prize. Royal Society. 12 September 2013.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Nicholas Lydon".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.